SCHEMBL723100

SCHEMBL723100

Cc1cc(Cl)cc(I)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.48
ALDH1A1 P00352 3/20 0.42
CYP3A4 P08684 2/20 0.42
RECQL P46063 2/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
ALOX5 P09917 1/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
ALB P02768 1/20 0.39
MAOA P21397 2/20 0.39
CHRM1 P11229 1/20 0.39
ALOX15 P16050 1/20 0.39
TBXA2R P21731 1/20 0.39
ADRA1A P35348 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7926703 0.89 TTR (0.58) TTRALDH1A1CYP3A4RECQLTSHR
SCHEMBL1182540 0.84 CA1 (0.58) ALDH1A1CYP3A4RECQLTSHRHSD17B10
SCHEMBL2933421 0.77 ALDH1A1 (0.44) ALDH1A1CYP3A4RECQLTSHRHSD17B10
SCHEMBL15064803 0.77 ALDH1A1 (0.43) ALDH1A1CYP3A4RECQLTSHRHSD17B10
SCHEMBL422660 0.77 HSD17B10 (0.65) TTRALDH1A1CYP3A4RECQLTSHR
SCHEMBL30804415 0.77 ALDH1A1 (0.65) TTRALDH1A1CYP3A4RECQLTSHR
SCHEMBL1893469 0.77 ALDH1A1 (0.65) TTRALDH1A1CYP3A4RECQLTSHR
SCHEMBL23907108 0.74 TTR (0.52) TTRALDH1A1CYP3A4CA1CA2
SCHEMBL815630 0.74 ALDH1A1 (0.54) TTRALDH1A1CA1CA2ALOX5
SCHEMBL7873607 0.74 TTR (0.78) TTRALDH1A1HSD17B10CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4712967-A2 G-PROTEIN COUPLED RECEPTOR ANTAGONIST Enveda Therapeutics, Inc. (US) 2026-03-25 EP disclosed
WO-2024239000-A2 G-PROTEIN COUPLED RECEPTOR ANTAGONIST ENVEDA THERAPEUTICS, INC. (US) 2024-11-21 WO disclosed
US-9522855-B2 Process for producing low molecular weight ethylene- and alpha-olefin-based materials DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-20 US disclosed
US-9522855-B2 Process for producing low molecular weight ethylene- and alpha-olefin-based materials DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-20 US disclosed
US-9522855-B2 Process for producing low molecular weight ethylene- and alpha-olefin-based materials DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-20 US disclosed
CN-105294905-A Process for polymerizing a polymerizable olefin and catalyst therefor DOW GLOBAL TECHNOLOGIES LLC 2016-02-03 CN disclosed
CN-103180347-B Process for polymerizing polymerizable olefins and catalyst therefor DOW GLOBAL TECHNOLOGIES LLC (US) 2015-12-02 CN disclosed
EP-2797962-B1 PROCESS FOR PRODUCING LOW MOLECULAR WEIGHT ETHYLENE- AND ALPHA-OLEFIN-BASED MATERIALS DOW GLOBAL TECHNOLOGIES LLC (US) 2015-11-18 EP disclosed
EP-2797962-B1 PROCESS FOR PRODUCING LOW MOLECULAR WEIGHT ETHYLENE- AND ALPHA-OLEFIN-BASED MATERIALS DOW GLOBAL TECHNOLOGIES LLC (US) 2015-11-18 EP disclosed
US-9029487-B2 Process for polymerizing a polymerizable olefin and catalyst therefor DOW GLOBAL TECHNOLOGIES LLC (US) 2015-05-12 US disclosed
CN-102906129-A Process for selectively polymerizing ethylene and catalyst therefor DOW GLOBAL TECHNOLOGIES LLC 2013-01-30 CN disclosed
EP-2491062-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR Dow Global Technologies LLC (US) 2012-08-29 EP disclosed
WO-2012027448-A1 PROCESS FOR POLYMERIZING A POLYMERIZABLE OLEFIN AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2012-03-01 WO disclosed
WO-2011146044-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2011-11-24 WO disclosed
WO-2011146044-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2011-11-24 WO disclosed
WO-2011146291-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2011-11-24 WO disclosed
WO-2011146291-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2011-11-24 WO disclosed
US-20110282018-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC 2011-11-17 US disclosed
US-20110282018-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC 2011-11-17 US disclosed
US-20110282018-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282018-A1 PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR WEE2, NOTUM, WEE1 TTR 4757/4885ALDH1A1 2392/4885CYP3A4 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.